monsRUS

monsRUS

The entry point is when the "rectangle" figure is broken. The strengthening factor is the previous upward price impulse. The price breaks through the upper border - the candlestick closes for the most part or completely higher, we immediately enter into a buy, or it is possible after a price rollback to the upper border. Stop Loss is set below the upper border of...

monsRUS

The figure of a cup with a handle, as well as a squeeze and an ascending triangle. Entry is possible after retesting the breakout line of the handle (triangle), so you eliminate the risk of a false breakout, but you will not get the best price, or you can place an order at the level and immediately open a long trade in the event of a breakdown of the resistance...

monsRUS Updated 

Enter the market only when the price decisively breaks the upper horizontal line. When trading, expect a breakout shortly after completing the triangle formation. When the price breaks the upper triangle line, this line becomes a support level. From experience, use a moving average to confirm a trend. stop after her

monsRUS

Share your opinion in the comments and support the idea with likes. Thank you for your support!

monsRUS

The entry point is when the "rectangle" figure is broken. The leveraging factor is the preceding upward momentum in price. The price breaks through the upper border - the candlestick closes for the most part or completely higher, we enter a buy right away or it is possible after the price rolls back to the upper border. Stop Loss is set below the upper border of...

monsRUS Updated 

On December 4, 2019, the merger of CBS Corporation and Viacom Inc. The combined company is renamed ViacomCBS . VIAC has around 30 million subscribers worldwide and streaming revenue of $ 3.6 billion. It is expected to grow to $ 7 billion by 2024 at an average annual growth rate of 30%. Over the year, the share price has risen by 800%, based on today's estimates,...

monsRUS

Intercept has been and potentially remains the leader in NASH. Stock prices plummeted in June 2020 after receiving a full response letter from the FDA to its new application for a drug to treat NASH with liver fibrosis. To date, the only commercial Intercept product, Ocaliva (obeticholic acid or OCA), is an approved drug for the treatment of primary biliary...

monsRUS

Share your opinion in the comments and support the idea with likes. Thank you for your support!

monsRUS

Share your opinion in the comments and support the idea with likes. Thank you for your support!

monsRUS

A figure of a cup with a handle. Entry after retesting the neck breakout line The moving average should always be below the handle.

monsRUS

Invitae's Q4 results remained the same as in previous quarters. The company has shown strong revenue growth, but remains consistently unprofitable. At the end of 2020, the company conducted 659,000 tests, which is 36.7% more than in 2019. Net loss was $ 608.9 million, or $ 4.52 per share, up from $ 242.0 million, or $ 2.66 per share, in the prior year. The...

monsRUS

Share your opinion in the comments and support the idea with likes. Thank you for your support!

monsRUS

Share your opinion in the comments and support the idea with likes. Thank you for your support!

monsRUS Updated 

At the moment, Bitcoin is growing, consolidated above the psychological mark of $ 50,000, the shares of MSTR, following the growth of Bitcoin, turned into a bullish rally. Enter on retest level 815, move potential 20%, stop 2%, after passing the first 3% we set without loss. Exit in parts. We constantly monitor the movement of Bitcoin to correct the exit point...

monsRUS

710-720 is a strong resistance level, which we will not pass in the near future. Today the trading session is expected to be short, long from the level in the rectangle pattern. Further, it is possible, but unlikely, the "Inverted GiP" pattern will work out We open a deal when the candlestick closes on the neckline breakout. Before the breakout, the "neckline"...

monsRUS

On March 9, the FDA identified flaws in ACADIA's application for a new drug for Pimavanserin to treat hallucinations and delusions associated with psychosis and dementia. By April 3, Acadia is likely to receive a full response letter from the FDA. DRP approval of Pimavanserin is unlikely, but possible. The stock bounced off 24.00, then 26.00 and 27.00. The figure...

monsRUS

Share your opinion in the comments and support the idea with likes. Thank you for your support!

monsRUS

Share your opinion in the comments and support the idea with likes. Thank you for your support!